Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer treatment, announced its participation in several upcoming investor conferences. Members of the senior management team will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026, with a presentation scheduled for 9:10 AM Eastern Time. They will also take part in the Leerink Annual Global Healthcare Conference in Miami on March 9, 2026, engaging in a fireside chat at 10:00 AM Eastern Time, and will participate in another fireside chat at the Citizens Life Science Conference on March 10, 2026, at 11:55 AM Eastern Time.

Investors and other interested parties can access live webcasts of each presentation through the Investors section of Lyell's website at www.lyell.com, with replays available shortly after the events.

Lyell’s focus is on enhancing CAR T-cell therapies to improve treatment outcomes for both hematologic malignancies and solid tumors. The company leverages proprietary technologies designed to equip CAR T cells with characteristics that promote prolonged tumor destruction and sustained clinical responses. Notably, Lyell's LyFE Manufacturing Center™ is capable of producing more than 1,200 CAR T-cell doses at full capacity, positioning the company for potential future commercial launches.

Investors should bear in mind that the announcement includes forward-looking statements that carry inherent risks and uncertainties, and that actual results may vary from the anticipated outcomes due to various factors. For more detailed insights and potential risks related to their operations, stakeholders are encouraged to review the company's filings with the Securities and Exchange Commission.

Lyell Immunopharma, Inc. (Nasdaq: LYEL) has announced its upcoming participation in key investor conferences in March 2026, which could present an opportunity for investors to reassess the company’s market position and growth trajectory within the CAR T-cell therapy sector. The presentations will occur at reputable events, including the TD Cowen 46th Annual Health Care Conference and the Leerink and Citizens Life Science Conferences in Miami, showcasing Lyell's commitment to raising investor awareness and engagement regarding its innovative pipeline.

Investors should pay close attention to Lyell's advancements in CAR T-cell therapies, particularly given the company’s innovative strategies designed to enhance therapeutic efficacy for cancer patients. With proprietary technologies that enhance CAR T cells' durability against tumor microenvironments, the company is positioning itself well within a competitive market that increasingly prioritizes effective cell therapies. The capacity showcased by Lyell’s LyFE Manufacturing Center™—which can produce over 1,200 CAR T-cell doses at peak efficiency—also signals a preparedness for commercial-scale operations, potentially enabling rapid scalability upon successful clinical outcomes.

However, it is important to remain cautious. The announcement included forward-looking statements identifying distinct risks and uncertainties that could impact future performance. Investors should carefully consider these risks, as delineated in previous filings, which could influence stock performance moving forward.

Ultimately, while Lyell offers a promising narrative driven by innovative treatments and robust manufacturing capabilities, potential investors should approach the stock with an informed perspective. Attend the webcasts to gather insights directly from management and assess whether Lyell’s strategic direction aligns with your investment goals. Monitoring the company’s conference performance and subsequent developments will be crucial in determining the potential trajectory of LYEL shares.